Welcome to our dedicated page for Pieris Pharmaceu news (Ticker: PIRS), a resource for investors and traders seeking the latest updates and insights on Pieris Pharmaceu stock.
Pieris Pharmaceuticals, Inc. (PIRS) delivers innovative biopharmaceutical solutions through its proprietary anticalin protein platform. This dedicated news hub provides investors and industry stakeholders with essential updates on clinical developments, strategic collaborations, and therapeutic advancements.
Track critical updates including clinical trial progress in immuno-oncology and respiratory therapies, partnership announcements with global pharmaceutical leaders, and regulatory milestones for novel anticalin-based treatments. Our curated news collection serves as a centralized resource for understanding PIRS's role in advancing precision-targeted therapeutics.
Discover timely updates on pipeline developments across key therapeutic areas and business strategy implementations. This repository is designed to help users monitor the company's progress in translating innovative protein engineering into clinical-stage assets.
Bookmark this page for streamlined access to Pieris Pharmaceuticals' latest announcements and scientific breakthroughs. Regularly updated to ensure you stay informed about this clinical-stage biotech innovator's evolving landscape.
Pieris Pharmaceuticals (PIRS) announced the presentation of preclinical data for PRS-220, a CTGF inhibitor for treating idiopathic pulmonary fibrosis (IPF), at the ERS International Congress 2021. The data highlights PRS-220's superior target engagement and lung penetration compared to a standard anti-CTGF antibody. Phase 1 studies are anticipated to begin next year. IPF impacts over three million patients globally, with limited treatment options.
Pieris Pharmaceuticals reported strong progress in its second quarter of 2021, advancing its pipeline while ending with a cash balance of over $119 million. Key highlights include the unveiling of PRS-220 for idiopathic pulmonary fibrosis (IPF) and a $17 million Bavarian government grant for post-COVID pulmonary fibrosis research. The company signed a collaboration agreement with Genentech, receiving a $20 million upfront payment and potential over $1.4 billion in future milestones. Despite a net loss of $15.5 million for the quarter, Pieris reiterated guidance for ongoing clinical studies.
Pieris Pharmaceuticals has appointed Tim Demuth, M.D., Ph.D., as Chief Medical Officer and promoted Shane Olwill, Ph.D., to Chief Development Officer. Dr. Demuth brings extensive experience in oncology drug development, having previously worked with Merck KGaA and Novartis AG. He will oversee clinical and regulatory efforts, while Dr. Olwill will lead translational activities. The company also granted Dr. Demuth stock options for 360,000 shares at $3.48 each. Both executives aim to progress Pieris' innovative therapies targeting respiratory diseases and immuno-oncology.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced it will host an investor call on August 4, 2021, at 8:00 AM EDT, to discuss financial results and provide a corporate update for the second quarter of 2021. Participants can join via phone or through a webcast. A replay will be available on the company’s website. Pieris is focused on advancing its proprietary Anticalin technology platform to develop therapies for respiratory diseases and cancer.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced the development of PRS-220, an oral inhaled Anticalin protein targeting CTGF for treating idiopathic pulmonary fibrosis (IPF). The company received a €14.2 million grant (approximately $17 million) from the Bavarian Ministry to evaluate PRS-220 for post-COVID-19-related pulmonary fibrosis (PASC-PF). Clinical development is set to begin in 2022. PRS-220 shows potential as a superior local treatment for these conditions.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced that the FDA granted orphan drug designation to cinrebafusp alfa (PRS-343) for treating HER2-high and HER2-low expressing gastric cancers. This designation supports the development of therapies for conditions affecting fewer than 200,000 U.S. patients annually. The company is set to begin a phase 2 trial later this summer, aiming to combine cinrebafusp alfa with ramucirumab and paclitaxel. Orphan status provides various incentives, including market exclusivity and FDA support for clinical trial design.
Pieris Pharmaceuticals has entered a research collaboration with Genentech, receiving an upfront payment of $20 million and potential milestone payments exceeding $1.4 billion. The collaboration focuses on therapies for respiratory diseases and ophthalmological conditions, utilizing Pieris' proprietary Anticalin technology. Genentech will handle clinical development and commercialization, while Pieris will lead discovery and early preclinical development. This partnership marks Pieris’ second alliance in the respiratory space, emphasizing its commitment to inhaled biologics.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced its participation in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, at 1:00 PM EDT. The webcast will be available here. The company focuses on novel biotherapeutics using its proprietary Anticalin® technology, targeting respiratory diseases and cancer. Their collaborations include partnerships with AstraZeneca and Seagen. For further details, visit www.pieris.com.
Pieris Pharmaceuticals (NASDAQ:PIRS) reported significant advancements with its biotherapeutics pipeline on May 17, 2021. The company initiated dosing for PRS-060/AZD1402 in a phase 2a study for asthma and plans to start a phase 2 study for cinrebafusp alfa (PRS-343) in gastric cancer this summer. Pieris secured a $10 million upfront payment from Boston Pharmaceuticals for a new collaboration on PRS-342 and may earn up to $353 million in milestones. Financially, Pieris reported a net loss of $4.2 million for Q1 2021, with cash reserves totaling $66.8 million.
Pieris Pharmaceuticals (NASDAQ:PIRS) will host a first quarter 2021 investor call on May 17, 2021, at 8:00 AM EDT. The call aims to discuss financial results and provide a corporate update. Participants can join by dialing 877-407-8920 (Toll-Free US & Canada) or 412-902-1010 (International). A listen-only audio webcast will also be available. A replay can be accessed through the company's website. Pieris specializes in developing Anticalin protein-based drugs for respiratory diseases and cancer.
